Susquehanna International Group’s RAPT Therapeutics RAPT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | – | Sell |
-424,862
| Closed | -$14.4M | – | 13933 |
|
|
2025
Q4 | $14.4M | Buy |
424,862
+379,480
| +836% | +$11.8M | ﹤0.01% | 2586 |
|
|
2025
Q3 | $1.17M | Buy |
+45,382
| New | +$594K | ﹤0.01% | 6978 |
|
|
2025
Q2 | – | Sell |
-5,207
| Closed | -$39.7K | – | 13541 |
|
|
2025
Q1 | $50.8K | Buy |
5,207
+1,515
| +41% | +$14.9K | ﹤0.01% | 11857 |
|
|
2024
Q4 | $46.7K | Buy |
3,692
+2,417
| +190% | +$30.7K | ﹤0.01% | 11705 |
|
|
2024
Q3 | $20.5K | Sell |
1,275
-117
| -8% | -$2.37K | ﹤0.01% | 11621 |
|
|
2024
Q2 | $34K | Sell |
1,392
-6,355
| -82% | -$294K | ﹤0.01% | 11535 |
|
|
2024
Q1 | $557K | Buy |
7,747
+5,531
| +250% | +$769K | ﹤0.01% | 8264 |
|
|
2023
Q4 | $441K | Buy |
+2,216
| New | +$274K | ﹤0.01% | 8977 |
|
|
2023
Q2 | – | Sell |
-6,171
| Closed | -$961K | – | 12943 |
|
|
2023
Q1 | $906K | Buy |
6,171
+4,298
| +229% | +$869K | ﹤0.01% | 7073 |
|
|
2022
Q4 | $297K | Sell |
1,873
-1,608
| -46% | -$257K | ﹤0.01% | 9128 |
|
|
2022
Q3 | $670K | Buy |
+3,481
| New | +$658K | ﹤0.01% | 7689 |
|
|
2022
Q2 | – | Sell |
-3,326
| Closed | -$443K | – | 13748 |
|
|
2022
Q1 | $585K | Sell |
3,326
-1,531
| -32% | -$289K | ﹤0.01% | 8574 |
|
|
2021
Q4 | $1.43M | Buy |
+4,857
| New | +$1.3M | ﹤0.01% | 6327 |
|
|
2021
Q3 | – | Sell |
-1,124
| Closed | -$297K | – | 13407 |
|
|
2021
Q2 | $286K | Sell |
1,124
-1,564
| -58% | -$292K | ﹤0.01% | 10865 |
|
|
2021
Q1 | $477K | Buy |
+2,688
| New | +$443K | ﹤0.01% | 9592 |
|
Susquehanna International Group's RAPT Position: Q1 2026 in Review
Susquehanna International Group sold out of RAPT Therapeutics (RAPT) in Q1 2026, closing a stake of 424,862 shares — an estimated $14.4M sold.
Susquehanna International Group first reported a position in RAPT in Q1 2021 and held it in 15 quarters. The position peaked at $14.4M in Q4 2025. 0 funds tracked by Wall St. Rank hold RAPT as of Q1 2026.
- Susquehanna International Group reported no remaining RAPT Therapeutics position as of Q1 2026 after selling out during the quarter.
- Susquehanna International Group sold 424,862 RAPT Therapeutics shares in Q1 2026, an estimated $14.4M.
- Susquehanna International Group first reported a position in RAPT Therapeutics in Q1 2021 and held it in 15 quarters.
- Susquehanna International Group's RAPT Therapeutics position peaked at $14.4M in Q4 2025.
- 0 funds tracked by Wall St. Rank held RAPT Therapeutics as of Q1 2026.
Based on Susquehanna International Group's 13F filing for Q1 2026, filed 15 May 2026.